Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BrainStorm Cell Therapeutics
Biotech
After knock back, BrainStorm aligns with FDA on ph. 3 ALS trial
A piece of the latest comeback strategy slotted into place when the biotech revealed a written agreement with the FDA on the design of a phase 3b.
Nick Paul Taylor
Apr 9, 2024 7:51am
VectorY raises $138M to push forward ALS program
Nov 13, 2023 10:26am
J&J's medtech chief out the door—Chutes & Ladders
Oct 27, 2023 9:30am
BrainStorm lays off 30%, details bid to reach ALS market
Oct 24, 2023 9:17am
BrainStorm eyes FDA meeting to find path for rejected drug
Oct 18, 2023 10:44am
FDA advisers resoundingly reject BrainStorm's ALS drug
Sep 27, 2023 6:04pm